Axogen saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 97.
Looking For The Best Stocks To Buy And Watch? Start Here
The new score tells you the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher rating in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
Axogen is trading about 4% above a 15.25 entry from a cup with handle.
The stock sports an 80 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company posted 0% EPS growth. Top line growth fell to 15%, down from 18% in the prior quarter. The company's next quarterly report is expected on or around May. 8.
Axogen earns the No. 4 rank among its peers in the Medical-Products industry group. Pro-Dex is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
